Eight healthcare categories. One network.
Solara's network carries portfolios across eight specialty-healthcare categories. Each has its own economics, its own rep profile, and its own set of things manufacturers in the space need to see before they launch. Here's what's in each one.
Medical Devices
& Durables.
Implantables, diagnostic hardware, DME, and surgical instruments — products that require physician-direct field sales and clinical fluency. Manufacturers in this category are Solara's foundational category.
Read the Devices breakdownImplantable devices, diagnostic capital equipment, durable medical equipment, surgical instruments and single-use procedural kits.
Deep clinical conversations, higher per-unit economics, and the kind of recurring procedure volume that compounds over months — not the quarterly reset of a pure pharma cycle.
Turnkey field coverage across priority IDNs. Physician-level adoption telemetry. Rep outcomes feed targeting for the next manufacturer in the category, tightening the floor as the category matures.
Clinical Data
& Coordination.
Risk adjustment, HEDIS gap closure, care management, and coordination platforms — the SaaS layer underneath modern primary care and specialty groups.
Read the Data breakdownRisk-adjustment platforms, HEDIS gap closure software, population health tooling, and care-coordination services sold into primary care, ACO, and MA plans.
Multi-year contract economics, executive buyers (CMO, Medical Director), and products that show up as line-items in the health plan — recurring relevance, recurring revenue.
Account-based targeting tuned to payer mix and ACO participation. Rep contribution attribution against multi-touch enterprise deals, not single-order line items.
Diagnostics
& Labs.
Molecular diagnostics, reference labs, and specialty testing — the category where rep volume and physician-fit matter most, and where Solara's ranking model earns its keep.
Read the Diagnostics breakdownMolecular and genomic diagnostics, specialty reference lab services, companion diagnostics, and point-of-care testing.
High per-order economics, frequent reorder cadence, and physician conversations anchored in clinical evidence — the kind of sales cycle where better targeting changes your month.
Specialty-specific rep coverage (oncology, cardiology, genetics) without the specialty-specific hiring drag. Ordering-physician adoption state tracked live, not through claim-lag.
Specialty Pharma
& Specialty.
Specialty pharmacy, limited-distribution drugs, and biosimilars — where payer context, formulary position, and prescriber relationship density determine who converts.
Read the Pharma breakdownSpecialty pharmacy networks, limited-distribution therapies, biosimilars, orphan and ultra-orphan drugs.
Focused prescriber universe, high-stakes conversations, and per-prescription economics that make every genuine relationship count. Small networks, durable earnings.
Payer-aware targeting, formulary-sensitive messaging, and real-time visibility into the specific prescribers who are evaluating, adopting, or churning.
Wound Care
& Regenerative.
Biologics, regenerative medicine, and advanced wound products — a category where site-of-service economics and physician adoption patterns move together.
Read the Wound Care breakdownSkin substitutes, amniotic and placental biologics, advanced dressings, and regenerative therapies sold into wound clinics and specialty practices.
Rep-driven adoption, procedural recurrence, and the kind of site-level champions who become reference accounts. Relationship economics compound here.
Coverage across wound clinics and procedural sites without building a category-specific rep org. Adoption state surfaced at the physician + site level.
DME
& Home.
Home medical equipment, CPAP, and respiratory diagnostics — where the sales motion is about referral pipelines and cross-referral networks, not one-off physician visits.
Read the DME breakdownHome medical equipment, CPAP and BiPAP, respiratory diagnostics, oxygen therapy, and home infusion-adjacent DME.
Referral-network economics, recurring resupply, and the kind of sticky relationships that compound once a provider pipeline is established.
Referral-network mapping, pipeline telemetry from order to fulfillment, and a rep network that already knows the cross-referral landscape.
Infusion
& In-office.
In-office infusion, buy-and-bill therapies, and specialty administration — where economics live at the practice level and the rep's job is making the revenue math obvious.
Read the Infusion breakdownIn-office infusion therapies, buy-and-bill specialty drugs, injectable administration services, and infusion-suite build-outs.
Executive conversations with practice administrators and MDs, recurring administration revenue for the practice, and per-treatment economics for the rep.
Administration-site targeting, payer-aware buy-and-bill economics modelling, and rep coverage at the practice-admin level — not just the prescriber.
Value-Based Care Enablement
& Value.
MSSP, REACH, Stars platforms, and VBC enablement — selling into the provider organizations retooling their revenue model around outcomes. Long cycles, durable partnerships.
Read the VBC breakdownMSSP and REACH ACO enablement, Medicare Advantage Stars improvement, quality measurement platforms, and provider-side VBC infrastructure.
Executive-level conversations (CMO, VP Pop Health, CFO), multi-year contracts, and the chance to carry the product that actually changes how a practice earns.
Account-based coverage of priority ACOs and MA-participating groups. Participation-year-aware messaging and executive-suite relationship density.
Selling into one of these? Let's talk.
Manufacturers — category-specific reference customers and rep availability shared under NDA. Reps — pick the categories you want to carry on the application form; we'll take it from there.